A movement to reposition tablets has been initiated in current years [1]. In this strategy, it is vital to use tablets which have been tested to be harmless and whose pharmacokinetics and most advantageous dosage are well known. In the current episode of novel coronavirus (SARS-CoV-2) emergence [2], we find a wonderful ex- enough of possible repositioning of tablets, especially chloroquine. We had 20 years ago proposed to systematically check chloroquine in viral infections as it have been proven to be powerful in vitro against a broad variety of viruses [3,4]. This drug has more than one activity, one among that's to alkalise the phagolysosome, which hampers the low-pH-based steps of viral replication, along with fusion and uncoating [4]. Other mechanisms of antiviral hobby are poorly explained [5].

References

1. Mullard A. “Drug repurposing programmes get lift off”. Nature Reviews Drug Discovery 7 (2012): 505-506.
2. Zhou P., et al. “A pneumonia out- break associated with a new coronavirus of probable bat origin”. Nature 7798 (2020): 270-273.
3. Savarino A., et al. “New insights into the antiviral effects of chloroquine”. Lancet Infectious Diseases 2 (2006): 67-69.
4. Rolain JM., et al. “Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21^st century”. International Journal of Antimicrobial Agents 4 (2007): 297-308.
5. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 2 (2005): 69.
6. Ksiazek TG., et al. “A novel coronavirus associated with severe acute respiratory syndrome”. New England Journal of Medicine 20 (2003): 1953-1966.
7. Balzarini J., et al. “Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics”. Antiviral Research 1 (2006): 20-33.
8. Keyaerts E., et al. “In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine”. Biochemical and Biophysical Research Communications 323 (2004): 264-268.
9. Barnard DL., et al. “Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice”. Antiviral Chemistry and Chemotherapy 17 (2006): 275-284.
10. de Wilde AH., et al. “Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture”. Antimicrobial Agents and Chemotherapy 8 (2014): 4875-4884.
11. Yu IT., et al. “Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy”. Clinical Infectious Diseases 5 (2014): 683-686.
12. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research 3 (2020): 269-271.
13. Agostini ML., et al. “Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease”. mBio2 (2018): e00221-18.
14. White NJ., et al. “Malaria”. Lancet 9918 (2014): 723-735.
15. Al-Bari MA. “Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases”. Journal of Antimicrobial Chemotherapy 70 (2015): 1608-1621.
16. Lee SJ., et al. “The role of antimalarial agents in the treatment of SLE and lupus nephritis”. Nature Reviews Nephrology 12 (2011): 718-729.

Citation

Citation: Indranil Chatterjee and Manas Chakraborty. “Chloroquine as Reposition Drugs for Novel Coronavirus SARS-COV-2 Emergence" Acta Scientific Microbiology 3.5 (2020): 37-38.

Copyright

Copyright: © 2020 Indranil Chatterjee and Manas Chakraborty. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.